Andexxa was granted accelerated approval by the FDA in May 2018.
Your search for apixaban returned 18 results
Risk up with amiodarone vs flecainide or sotalol among seniors with atrial fibrillation receiving apixaban or rivaroxaban.
Asundexian is an investigational oral Factor XIa inhibitor.
Apixaban dominated enoxaparin and edoxaban; rivaroxaban was slightly more effective than apixaban
No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons
FDA Panel votes on the potential removal from the market of Makena; results from an apixaban trial of patients with atrial fibrillation and valvular heart disease; reports of serious ocular complications with monkeypox infection; the novavax vaccine becomes the latest authorized COVID-19 booster; and treatments for nephropathy and ALS have their review period extended.
Apixaban and rivaroxaban are both factor Xa inhibitors.
Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery
Abelacimab is a highly selective, fully human monoclonal antibody designed to inhibit both factor XI and its activated form, factor XIa.
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.